在肺腺癌中,KRAS突变通过ETV4促进PD-L1介导的免疫逃脱
Daqi Jia1, Peng Wang1, Shiqi Zheng1
1Department of Pathology, 920th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Kunming, Yunnan, China.
Translational oncology
|September 14, 2025
概括
肺腺癌中的KRAS突变通过MEK-ERK-ETV4通路增加PD-L1的表达. 这种机制驱动免疫逃生,为肺癌提供潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- KRAS突变是肺腺癌的常见驱动因素.
- 这些突变通常与免疫逃避有关,阻碍了抗瘤反应.
- 编程死亡配体1 (PD-L1) 是免疫抑制的关键调解者.
研究的目的:
- 阐明KRAS突变调高PD-L1.1的分子机制.
- 研究KRAS驱动的PD-L1表达在肺腺癌中免疫逃逸中的作用.
- 确定关键的信号通路和转录因子参与这个过程.
主要方法:
- 对转录组和GEO数据库数据的分析,以及免疫组织化学.
- 功能性研究涉及KRAS淘汰和MEK-ERK通路抑制.
- 权重基因联合表达网络分析 (WGCNA),转录因子结合部位预测 (JASPAR),光酶试验和ChIP实验.
主要成果:
- 在KRAS突变肺腺癌中,PD-L1表达显著升高.
- MEK-ERK信号通路是PD-L1上调的主要媒介.
- 克拉斯突变通过转录因子ETV4增强PD-L1表达,该转录因子直接与PD-L1促进体结合.
结论:
- 肺腺癌中的KRAS突变通过MEK-ERK-ETV4信号轴调节PD-L1的表达.
- ETV4作为一个关键的转录因子,激活PD-L1表达.
- 这一途径促进了KRAS突变肺腺癌的免疫逃生,突出了ETV4作为潜在的治疗点.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
25.0K
相关概念视频
The Ras Gene
7.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.1K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
